Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study.

van de Loo AJAE, Bervoets AC, Mooren L, Bouwmeester NH, Garssen J, Zuiker R, van Amerongen G, van Gerven J, Singh J, der Ark PV, Fedgchin M, Morrison R, Wajs E, Verster JC.

Psychopharmacology (Berl). 2017 Nov;234(21):3175-3183. doi: 10.1007/s00213-017-4706-6. Epub 2017 Jul 28.

2.

Looking for the Self: Phenomenology, Neurophysiology and Philosophical Significance of Drug-induced Ego Dissolution.

Millière R.

Front Hum Neurosci. 2017 May 23;11:245. doi: 10.3389/fnhum.2017.00245. eCollection 2017.

3.

Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.

Maksymetz J, Moran SP, Conn PJ.

Mol Brain. 2017 Apr 26;10(1):15. doi: 10.1186/s13041-017-0293-z. Review.

4.

Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant.

Zhu W, Ding Z, Zhang Y, Shi J, Hashimoto K, Lu L.

Neurosci Bull. 2016 Dec;32(6):557-564. Epub 2016 Nov 22. Review.

PMID:
27878517
5.

Ketamine enantiomers in the rapid and sustained antidepressant effects.

Muller J, Pentyala S, Dilger J, Pentyala S.

Ther Adv Psychopharmacol. 2016 Jun;6(3):185-92. doi: 10.1177/2045125316631267. Epub 2016 Mar 10. Review.

6.

Are Hallucinations Due to an Imbalance Between Excitatory and Inhibitory Influences on the Brain?

Jardri R, Hugdahl K, Hughes M, Brunelin J, Waters F, Alderson-Day B, Smailes D, Sterzer P, Corlett PR, Leptourgos P, Debbané M, Cachia A, Denève S.

Schizophr Bull. 2016 Sep;42(5):1124-34. doi: 10.1093/schbul/sbw075. Epub 2016 Jun 3. Review.

7.

Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys.

Hashimoto K, Kakiuchi T, Ohba H, Nishiyama S, Tsukada H.

Eur Arch Psychiatry Clin Neurosci. 2017 Mar;267(2):173-176. doi: 10.1007/s00406-016-0692-7. Epub 2016 Apr 18.

8.

KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.

Abdallah CG, Adams TG, Kelmendi B, Esterlis I, Sanacora G, Krystal JH.

Depress Anxiety. 2016 Aug;33(8):689-97. doi: 10.1002/da.22501. Epub 2016 Apr 6. Review.

9.

The novel ketamine analog methoxetamine produces dissociative-like behavioral effects in rodents.

Halberstadt AL, Slepak N, Hyun J, Buell MR, Powell SB.

Psychopharmacology (Berl). 2016 Apr;233(7):1215-25. doi: 10.1007/s00213-016-4203-3. Epub 2016 Jan 13.

10.

Ketamine-Induced Hallucinations.

Powers AR 3rd, Gancsos MG, Finn ES, Morgan PT, Corlett PR.

Psychopathology. 2015;48(6):376-85. doi: 10.1159/000438675. Epub 2015 Sep 12.

11.

R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects.

Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, Dong C, Hashimoto K.

Transl Psychiatry. 2015 Sep 1;5:e632. doi: 10.1038/tp.2015.136.

12.

Clinical Electroencephalography for Anesthesiologists: Part I: Background and Basic Signatures.

Purdon PL, Sampson A, Pavone KJ, Brown EN.

Anesthesiology. 2015 Oct;123(4):937-60. doi: 10.1097/ALN.0000000000000841. Review.

13.

Enantioselective inhibition of d-serine transport by (S)-ketamine.

Singh NS, Bernier M, Camandola S, Khadeer MA, Moaddel R, Mattson MP, Wainer IW.

Br J Pharmacol. 2015 Jul 3. doi: 10.1111/bph.13239. [Epub ahead of print]

14.

Ketamine and phencyclidine: the good, the bad and the unexpected.

Lodge D, Mercier MS.

Br J Pharmacol. 2015 Sep;172(17):4254-76. doi: 10.1111/bph.13222. Epub 2015 Jul 28. Review.

15.

Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.

Abdallah CG, Sanacora G, Duman RS, Krystal JH.

Annu Rev Med. 2015;66:509-23. doi: 10.1146/annurev-med-053013-062946. Epub 2014 Oct 17. Review.

16.

Identification of developmentally regulated PCP-responsive non-coding RNA, prt6, in the rat thalamus.

Takebayashi H, Yamamoto N, Umino A, Nishikawa T.

PLoS One. 2014 Jun 2;9(6):e97955. doi: 10.1371/journal.pone.0097955. eCollection 2014.

17.

The R-Stereoisomer of Ketamine as an Alternative for Ketamine for Treatment-resistant Major Depression.

Hashimoto K.

Clin Psychopharmacol Neurosci. 2014 Apr;12(1):72-3. doi: 10.9758/cpn.2014.12.1.72. Epub 2014 Apr 24. No abstract available.

18.

Reply to: Rapid antidepressant effects and abuse liability of ketamine.

Hillhouse TM, Porter JH, Negus SS.

Psychopharmacology (Berl). 2014 May;231(9):2043-4. No abstract available.

19.

Subanesthetic ketamine treatment promotes abnormal interactions between neural subsystems and alters the properties of functional brain networks.

Dawson N, McDonald M, Higham DJ, Morris BJ, Pratt JA.

Neuropsychopharmacology. 2014 Jun;39(7):1786-98. doi: 10.1038/npp.2014.26. Epub 2014 Feb 4.

20.

To use or not to use: an update on licit and illicit ketamine use.

Li JH, Vicknasingam B, Cheung YW, Zhou W, Nurhidayat AW, Jarlais DC, Schottenfeld R.

Subst Abuse Rehabil. 2011 Mar 16;2:11-20. doi: 10.2147/SAR.S15458. eCollection 2011. Review.

Supplemental Content

Support Center